These findings suggest that angiotensin receptor blockers like losartan may help prevent diabetes-induced remodeling of the GI tract, whereas mineralocorticoid receptor antagonists do not provide the same level of protection. The gene discussed is NR3C2; the disease is diabetes mellitus.